Cost effectiveness of Fingolimod (Gilenya®) for the treatment of highly active relapsing-remitting multiple sclerosis.
|03/12/10||January 2011||Full Pharmacoeconomic Evaluation recommended|
|03/06/11||20/09/11||Reimbursement not recommended at the submitted price|
22nd September 2011
Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.